This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Investors Undervaluing Labcorp (LH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Labcorp (LH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles
by Zacks Equity Research
LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024.
Labcorp (LH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 1.47% and 0.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Labcorp (LH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Labcorp (LH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.
Labcorp Set to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
In the fourth quarter of 2024, LH is likely to have witnessed strong growth in both diagnostics and biopharma laboratory services.
Labcorp (LH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. ALGN: Which Stock Is the Better Value Option?
Top Research Reports for Meta Platforms, Wells Fargo & GE Aerospace
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Wells Fargo & Company (WFC) and GE Aerospace (GE), as well as a micro-cap stock Cemtrex, Inc. (CETX).
Inogen Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Merit Medical Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
MMSI's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Why Labcorp (LH) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
LH vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. WST: Which Stock Is the Better Value Option?
Is Labcorp (LH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should You Retain Labcorp Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are increasingly optimistic about LH due to its focus on high-growth areas and strategic partnerships.
Labcorp's New Alliance With Graves Gilbert Clinic Set to Boost Stock
by Zacks Equity Research
LH announces strategic agreement with Graves Gilbert Clinic for lab operations.
Tempus AI Stock Plunges 28.9% in Three Months: What's Next?
by Debanjana Dey
TEM is enhancing its offerings and expanding the breadth of products and services to improve patient care. However, macro challenges are likely to hurt its performance.
Labcorp Launches H5 Bird Flu Test Amid US Outbreak: Stock to Gain?
by Zacks Equity Research
LH's new H5 bird flu test, developed in collaboration with the CDC, is now available in the United States.
LH Stock May Gain From Select MAWD Pathology Asset Purchase Deal
by Zacks Equity Research
Labcorp is set to acquire select assets of MAWD Pathology Group.
Henry Schein (HSIC) Up 6.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors are increasingly optimistic about LH due to its partnerships and operational discipline.
Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain?
by Zacks Equity Research
LH launches new enhancements to Global Trial Connect to streamline site workflow.
LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains
by Zacks Equity Research
Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.